Jeffrey Walch
Stock Analyst at Bernstein
(2.50)
# 3,056
Out of 4,690 analysts
20
Total ratings
66.7%
Success rate
8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Upgraded: Hold | $9.8 → $12 | $13.73 | -13.33% | 5 | Aug 25, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $376 | $237.10 | +58.58% | 1 | Aug 24, 2026 | |
| RVMD Revolution Medicines | Maintained: Hold | $151 → $179 | $207.88 | -13.89% | 4 | Aug 20, 2026 | |
| INCY Incyte | Reiterated: Hold | $99 → $104 | $124.37 | -16.38% | 2 | Aug 12, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $221 → $218 | $154.06 | +41.50% | 3 | Aug 12, 2026 | |
| BNTX BioNTech SE | Maintained: Hold | $96 | $102.08 | -5.95% | 3 | Aug 4, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Hold | $229 | $244.54 | -6.35% | 2 | Jun 8, 2026 |
Summit Therapeutics
Aug 25, 2026
Upgraded: Hold
Price Target: $9.8 → $12
Current: $13.73
Upside: -13.33%
Alnylam Pharmaceuticals
Aug 24, 2026
Maintained: Buy
Price Target: $376
Current: $237.10
Upside: +58.58%
Revolution Medicines
Aug 20, 2026
Maintained: Hold
Price Target: $151 → $179
Current: $207.88
Upside: -13.89%
Incyte
Aug 12, 2026
Reiterated: Hold
Price Target: $99 → $104
Current: $124.37
Upside: -16.38%
Neurocrine Biosciences
Aug 12, 2026
Maintained: Buy
Price Target: $221 → $218
Current: $154.06
Upside: +41.50%
BioNTech SE
Aug 4, 2026
Maintained: Hold
Price Target: $96
Current: $102.08
Upside: -5.95%
Jazz Pharmaceuticals
Jun 8, 2026
Reiterated: Hold
Price Target: $229
Current: $244.54
Upside: -6.35%